The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Liposome-based drug co-delivery systems in cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sun, L., Zhou, D., Zhang, P., Li, Q.-H., & Liu, P. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.052 · Cited by 25
RetractedNanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Metals, Toxicity and Oxidative Stress
Valko, M., Morris, H., & Cronin, M. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053764635 · Cited by 5,018
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Self-citationHannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Liposomes as nanomedical devices
Bozzuto, G., & Molinari, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s68861 · Cited by 2,261
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells
Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J., & Conklin, D. S. (2002) · Genes & Development · doi:10.1101/gad.981002 · Cited by 1,552
Gene silencing in mammals by small interfering RNAs
McManus, M. T., & Sharp, P. A. (2002) · Nature Reviews Genetics · doi:10.1038/nrg908 · Cited by 1,399
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Trace elements in human physiology and pathology: zinc and metallothioneins
Tapiero, H., & Tew, K. D. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(03)00081-7 · Cited by 1,298
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Kim, B. Y. S., Rutka, J. T., & Chan, W. C. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912273 · Cited by 1,147
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,125
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application
Naseri, N., Valizadeh, H., & Zakeri-Milani, P. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.043 · Cited by 1,116
Elevated copper and oxidative stress in cancer cells as a target for cancer treatment
Gupte, A., & Mumper, R. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.004 · Cited by 1,036
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Trace elements in human physiology and pathology. Copper
Tapiero, H., Townsend, D. M., & Tew, K. D. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(03)00012-x · Cited by 1,007
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Haran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934
C ERULOPLASMIN M ETABOLISM AND F UNCTION
Hellman, N. E., & Gitlin, J. D. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.012502.114457 · Cited by 933
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Yeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Copper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Polymeric nanoparticles for targeted drug delivery system for cancer therapy
Masood, F. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2015.11.067 · Cited by 702
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Elnakat, H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.001 · Cited by 649
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 634
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Muthu, M. S., Leong, D. T., Mei, L., & Feng, S.-S. (2014) · Theranostics · doi:10.7150/thno.8698 · Cited by 603
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
The transferrin receptor: role in health and disease
Ponka, P., & Lok, C. N. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00070-9 · Cited by 595
Arredondo, M., & Núñez, M. T. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.010 · Cited by 550
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Application of gold nanoparticles in biomedical and drug delivery
Daraee, H., Eatemadi, A., Abbasi, E., Fekri Aval, S., Kouhi, M., & Akbarzadeh, A. (2016) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.3109/21691401.2014.955107 · Cited by 541
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Hyaluronan-Cell Interactions in Cancer and Vascular Disease
Toole, B. P., Wight, T. N., & Tammi, M. I. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100039200 · Cited by 491
Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation
Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar200054n · Cited by 476
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Transferrin/transferrin receptor‐mediated drug delivery
Li, H., & Qian, Z. M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10008 · Cited by 441
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Xiong, X.-B., & Lavasanifar, A. (2011) · ACS Nano · doi:10.1021/nn2013707 · Cited by 411
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient
Mayer, L. D., Bally, M. B., & Cullis, P. R. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90105-7 · Cited by 379
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Narayanan, N. K., Nargi, D., Randolph, C., & Narayanan, B. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24336 · Cited by 353
The normal structure and function of CD44 and its role in neoplasia
Sneath, R. J., & Mangham, D. C. (1998) · Molecular Pathology · doi:10.1136/mp.51.4.191 · Cited by 332
Mayer, L. D., Harasym, T. O., Tardi, P. G., Harasym, N. L., Shew, C. R., Johnstone, S. A., Ramsay, E. C., Bally, M. B., & Janoff, A. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0118 · Cited by 331
Eliaz, R. E., & Szoka, F. C. (2001) · PubMed · Cited by 330
Platinum‐based anticancer agents: Innovative design strategies and biological perspectives
Ho, Y., Au‐Yeung, S. C. F., & To, K. K. W. (2003) · Medicinal Research Reviews · doi:10.1002/med.10038 · Cited by 329
Daniel, K. G., Chen, D., Orlu, S., Cui, Q. C., Miller, F. R., & Dou, Q. P. (2005) · Breast Cancer Research · doi:10.1186/bcr1322 · Cited by 326
Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3017 · Cited by 317
Feldman, E. J., Lancet, J. E., Kolitz, J. E., Ritchie, E. K., Roboz, G. J., List, A. F., Allen, S. L., Asatiani, E., Mayer, L. D., Swenson, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5961 · Cited by 310
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Linder, M., Wooten, L., Cerveza, P., Cotton, S., Shulze, R., & Lomeli, N. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.5.965s · Cited by 267
In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
de Menezes, D. E. L., Pilarski, L. M., & Allen, T. M. (1998) · PubMed · Cited by 257
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Drug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Sajja, H., East, M., Mao, H., Wang, Y., Nie, S., & Yang, L. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581066 · Cited by 250
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
Ho, D., Wang, C.-H. K., & Chow, E. K.-H. (2015) · Science Advances · doi:10.1126/sciadv.1500439 · Cited by 242
Meng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D. (2016) · Scientific Reports · doi:10.1038/srep22390 · Cited by 236
Kurbacher, C. M., Wagner, U., Kolster, B., Andreotti, P. E., Krebs, D., & Bruckner, H. W. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04212-7 · Cited by 235
Copper in Medicine: Homeostasis, Chelation Therapy and Antitumor Drug Design
Wang, T., & Guo, Z. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776055742 · Cited by 233
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Co-delivery of drugs and plasmid DNA for cancer therapy
Teo, P. Y., Cheng, W., Hedrick, J. L., & Yang, Y. Y. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.014 · Cited by 229
Ramasamy, T., Haidar, Z. S., Tran, T. H., Choi, J. Y., Jeong, J.-H., Shin, B. S., Choi, H.-G., Yong, C. S., & Kim, J. O. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.08.021 · Cited by 224
Zhu, L., Perche, F., Wang, T., & Torchilin, V. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.060 · Cited by 220
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 216
Vascular Complications of Cancer Chemotherapy
Cameron, A. C., Touyz, R. M., & Lang, N. N. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.12.023 · Cited by 214
Polymer-Caged Nanobins for Synergistic Cisplatin−Doxorubicin Combination Chemotherapy
Lee, S.-M., O’Halloran, T. V., & Nguyen, S. T. (2010) · Journal of the American Chemical Society · doi:10.1021/ja107333g · Cited by 213
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S. K. L., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 213
Assanhou, A. G., Li, W., Zhang, L., Xue, L., Kong, L., Sun, H., Mo, R., & Zhang, C. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.022 · Cited by 207
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment
Kang, L., Gao, Z., Huang, W., Jin, M., & Wang, Q. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.03.001 · Cited by 195
Ligand-targeted theranostic nanomedicines against cancer
Yao, V. J., D'Angelo, S., Butler, K. S., Theron, C., Smith, T. L., Marchiò, S., Gelovani, J. G., Sidman, R. L., Dobroff, A. S., Brinker, C. J., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.002 · Cited by 195
Silencing or Stimulation? siRNA Delivery and the Immune System
Whitehead, K. A., Dahlman, J. E., Langer, R. S., & Anderson, D. G. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114133 · Cited by 191
Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.16-1995 · Cited by 188
Delivery of oligonucleotides with lipid nanoparticles
Wang, Y., Miao, L., Satterlee, A., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.007 · Cited by 184
Design of liposomal formulations for cell targeting
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.09.034 · Cited by 173
Liu, Y., Fang, J., Kim, Y.-J., Wong, M. K., & Wang, P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5000373 · Cited by 172
Maruyama, K., Takahashi, N., Tagawa, T., Nagaike, K., & Iwatsuru, M. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00905-8 · Cited by 170
Formation of transition metal–doxorubicin complexes inside liposomes
Abraham, S. A., Edwards, K., Karlsson, G., MacIntosh, S., Mayer, L. D., McKenzie, C., & Bally, M. B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00507-2 · Cited by 168
Copper deficiency as an anti-cancer strategy.
Goodman, V. L., Brewer, G. J., & Merajver, S. D. (2004) · Endocrine-related cancer · doi:10.1677/erc.0.0110255 · Cited by 168
Potential of Liposomes for Enhancement of Oral Drug Absorption
Daeihamed, M., Dadashzadeh, S., Haeri, A., & Akhlaghi, M. F. (2016) · Current Drug Delivery · doi:10.2174/1567201813666160115125756 · Cited by 159
Zhao, F., Yin, H. Y., & Li, J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.044 · Cited by 158
Applications of Nanoparticles for Anticancer Drug Delivery: A Review
Zhu, Y., & Liao, L. (2014) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2015.10298 · Cited by 157
Eloy, J. O., Petrilli, R., Topan, J. F., Antônio, H. M. R., Barcellos, J. P. A., Chesca, D. L., Serafini, L. N., Tiezzi, D. G., Lee, R. J., & Marchetti, J. M. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.01.032 · Cited by 157
Multidrug-resistant breast cancer: current perspectives
Tomlinson, D. C., Martin, H. L., & Smith, L. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s37638 · Cited by 154
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
Yu, Y. H., Kim, E. J., Park, D. E., Shim, G., Lee, S. B., Kim, Y. B., Kim, C., & Oh, Y. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.002 · Cited by 154
Doxorubicin Changes Bax /Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells
Sharifi, S., Barar, J., Hejazi, M. S., & Samadi, N. (2015) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2015.049 · Cited by 154
Self-citationFeng, Q., Yu, M., Wang, J., Hou, W., Gao, L., Ma, X., Pei, X.-W., Niu, Y.-J., Liu, X.-Y., Qiu, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.012 · Cited by 152
Dai, X., & Tan, C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.010 · Cited by 149
Wong, M.-Y., & Chiu, G. N. C. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.02.001 · Cited by 146
Ruttala, H. B., & Ko, Y. T. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.02.040 · Cited by 141
Sun, X., Pang, Z., Ye, H., Qiu, B., Guo, L., Li, J., Ren, J., Qian, Y. J., Zhang, Q., Chen, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.035 · Cited by 139
Milacic, V., Chen, D., Giovagnini, L., Diez, A., Fregona, D., & Dou, Q. P. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.03.009 · Cited by 139
Glasgow, M. D. K., & Chougule, M. B. (2015) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.2145 · Cited by 139
Wang, S., Sun, Zhu, Du, Liu, & Qian, W.-Y. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s34773 · Cited by 135
Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer
Qu, M., Zeng, R., Fang, S., Dai, Q., Li, H., & Long, J. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.019 · Cited by 134
Tsouris, V., Joo, M. K., Kim, S. H., Kwon, I. C., & Won, Y. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.05.006 · Cited by 133
Piva, R., Spandidos, D. A., & Gambari, R. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2059 · Cited by 132
Anticopper therapy against cancer and diseases of inflammation and fibrosis
Brewer, G. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03541-5 · Cited by 131
Sabzichi, M., Hamishehkar, H., Ramezani, F., Sharifi, S., Tabasinezhad, M., Pirouzpanah, M., Ghanbari, P., & Samadi, N. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.13.5311 · Cited by 127
Self-citationCopper−Doxorubicin as a Nanoparticle Cargo Retains Efficacy with Minimal Toxicity
Kheirolomoom, A., Mahakian, L. M., Lai, C.-Y., Lindfors, H. A., Seo, J. W., Paoli, E. E., Watson, K. D., Haynam, E. M., Ingham, E. S., Li, X., et al. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100245u · Cited by 124
Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent
Riordan, N. H., Riordan, H. D., Meng, X., Li, Y., & Jackson, J. A. (1995) · Medical Hypotheses · doi:10.1016/0306-9877(95)90137-x · Cited by 124
Application of cationic liposomes for delivery of nucleic acids
Shim, G., Kim, M., Park, J. Y., & Oh, Y. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.009 · Cited by 123
Tardi, P. G., Santos, N. D., Harasym, T. O., Johnstone, S. A., Zisman, N., Tsang, A. W., Bermudes, D. G., & Mayer, L. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0243 · Cited by 122
Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics
Marchal, S., Hor, A. E., Millard, M., Gillon, V., & Bezdetnaya, L. (2015) · Drugs · doi:10.1007/s40265-015-0453-3 · Cited by 117
Roles of the Bcl-2/Bax Ratio, Caspase-8 and 9 in Resistance of Breast Cancer Cells to Paclitaxel
Sharifi, S., Barar, J., Hejazi, M. S., & Samadi, N. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.20.8617 · Cited by 117
Self-citationCombinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 117
Gabizón, A., Tzemach, D., Gorin, J., Mak, L., Amitay, Y., Shmeeda, H., & Zalipsky, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1132-4 · Cited by 116
Ramadass, S. K., Anantharaman, N. V., Subramanian, S., Sivasubramanian, S., & Madhan, B. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.11.005 · Cited by 112
Bramson, J. L., Hitt, M., Gallichan, W. S., Rosenthal, K. L., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.3-333 · Cited by 109
Lönnerdal, B. L. (1996) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/63.5.821 · Cited by 108
Yang, T., Li, B., Qi, S., Liu, Y., Gai, Y., Ye, P., Yang, G., Zhang, W., Zhang, P., He, X., et al. (2014) · Theranostics · doi:10.7150/thno.9423 · Cited by 108
Nanocarriers in Gene Therapy: A Review
Xu, H., Li, Z., & Jin, S. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2044 · Cited by 107
Clemons, K. V., & Stevens, D. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.4.899 · Cited by 105
Shim, G., Han, S.-E., Yu, Y.-H., Lee, S. B., Lee, H. Y., Kim, K., Kwon, I. C., Park, T. G., Kim, Y. B., Choi, Y. S., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.017 · Cited by 101
Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours
Casciari, J. J., Riordan, N. H., Schmidt, T. L., Meng, X., Jackson, J. A., & Riordan, H. D. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1814 · Cited by 101
pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery
Zhang, N., Su, Z., Liang, Y., & Yao, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s90524 · Cited by 99
Potency of siRNA versus shRNA mediated knockdown in vivo
McAnuff, M. A., Rettig, G. R., & Rice, K. G. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20968 · Cited by 97
Gao, J., Chen, H., Yu, Y., Song, J., Song, H., Su, X., Li, W., Tong, X., Qian, W., Wang, H., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.088 · Cited by 97
Loading of doxorubicin into liposomes by forming Mn2+-drug complexes
Cheung, B. C. L., Sun, T. H. T., Leenhouts, J. M., & Cullis, P. R. (1998) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00168-0 · Cited by 96
Sugano, M., Egilmez, N. K., Yokota, S. J., Chen, F.-A., Harding, J., Huang, S. K., & Bankert, R. B. (2000) · PubMed · Cited by 93
Nanoparticle therapeutics: Technologies and methods for overcoming cancer
Cerqueira, B. B. S., Lasham, A., Shelling, A. N., & Al‐Kassas, R. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.10.007 · Cited by 93
Cevc, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.005 · Cited by 91
Yuba, E., Kanda, Y., Yoshizaki, Y., Teranishi, R., Harada, A., Sugiura, K., Izawa, T., Yamate, J., Sakaguchi, N., Koiwai, K., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.031 · Cited by 88
Zucker, D., Andriyanov, A. V., Steiner, A., Raviv, U., & Barenholz, Y. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.003 · Cited by 88
Al-Ahmady, Z. S., Chaloin, O., & Kostarelos, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.10.013 · Cited by 86
Fenske, D. B., Wong, K. F., Maurer, E., Maurer, N., Leenhouts, J. M., Boman, N. L., Amankwa, L. N., & Cullis, P. R. (1998) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00166-7 · Cited by 84
Shaikh, I. M., Tan, K.-B., Chaudhury, A., Liu, Y., Tan, B.-J., Tan, B. M. J., & Chiu, G. N. C. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.025 · Cited by 83
Ju, R.-J., Li, X., Shi, J., Li, X., Sun, M., Zeng, F., Zhou, J., Liu, L., Zhang, C.-X., Zhao, W., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.040 · Cited by 82
Peng, Z., Wang, C., Fang, E., Lu, X., Wang, G., & Tong, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092924 · Cited by 82
Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes
El-Nesr, O. H., Yahiya, S. A., & El-Gazayerly, O. N. (2010) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2010.07.003 · Cited by 79
Zucker, D., & Barenholz, Y. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.024 · Cited by 77
Zhang, Q., Ran, R., Zhang, L., Liu, Y., Mei, L., Zhang, Z., Gao, H., & He, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.010 · Cited by 77
Development of a Novel Method for Formulating Stable siRNA-Loaded Lipid Particles for In vivo Use
Wu, S. Y., Tom, L. N., Liang, M., Chang, H.-I., Davies, N. M., & McMillan, N. A. J. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9766-1 · Cited by 73
Regulation of MicroRNA by Antagomirs
Mattes, J., Yang, M., & Foster, P. S. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0227tr · Cited by 73
Revisiting vitamin C and cancer
Reczek, C. R., & Chandel, N. S. (2015) · Science · doi:10.1126/science.aad8671 · Cited by 73
Huang, Y., Cole, S. P. C., Cai, T., & Cai, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4596 · Cited by 68
Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA
Chang, R. S., Suh, M. S., Kim, S., Shim, G., Lee, S. B., Han, S., Lee, K. E., Jeon, H., Choi, H.-G., Choi, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.017 · Cited by 67
Functional liposomes in the cancer-targeted drug delivery
Tila, D., Ghasemi, S., Yazdani-Arazi, S. N., & Ghanbarzadeh, S. (2015) · Journal of Biomaterials Applications · doi:10.1177/0885328215578111 · Cited by 66
Recent Progress in Multidrug Delivery to Cancer Cells by Liposomes
Mo, R., Jiang, T., & Gu, Z. (2014) · Nanomedicine · doi:10.2217/nnm.14.62 · Cited by 64
Review peptide‐targeted liposomes for selective drug delivery: Advantages and problematic issues
Accardo, A., & Morelli, G. (2015) · Biopolymers · doi:10.1002/bip.22678 · Cited by 62
Combinatorial nanomedicines for colon cancer therapy
Anitha, A., Maya, S., Sivaram, A. J., Mony, U., & Jayakumar, R. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1353 · Cited by 62
Bao, Q., Zhang, N., Geng, D., Xue, J., Merritt, M., Zhang, C., & Ding, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.10.040 · Cited by 60
Spatiotemporal control of microRNA function using light-activated antagomirs
Connelly, C. M., Uprety, R., Hemphill, J., & Deiters, A. (2012) · Molecular BioSystems · doi:10.1039/c2mb25175b · Cited by 60
Kim, K. G., Liu, Y., Li, S., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500754r · Cited by 58
Inhibition of Survivin Restores the Sensitivity of Breast Cancer Cells to Docetaxel and Vinblastine
Ghanbari, P., Mohseni, M. M., Tabasinezhad, M., Yousefi, B., Saei, A. A., Sharifi, S., Rashidi, M., & Samadi, N. (2014) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-014-1125-6 · Cited by 54
Self-citationZeng, F., Ju, R., Liu, L., Xie, H.-J., Mu, L.-M., Zhao, Y. L., Yan, Y., Hu, Y., Wu, J.-S., & Lü, W.-L. (2015) · Oncotarget · doi:10.18632/oncotarget.5382 · Cited by 52
Dendrimers for theranostic applications
Sk, U. H., & Kojima, C. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0012 · Cited by 51
Sphingosin 1-phosphate contributes in tumor progression
Samadi, N., Tabasinezhad, M., Ghanbari, P., Mohseni, M. M., Saei, A. A., Sharifi, S., Saeedi, N., & Pourhassan, A. (2013) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.126446 · Cited by 50
Self-citationSmart nanocarriers for pH-triggered targeting and release of hydrophobic drugs
Cajot, S., Butsele, K. V., Paillard, A., Passirani, C., Garcion, E., Benoît, J., Varshney, S., & Jérôme, C. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.08.049 · Cited by 50
Lü, W.-L., Ju, R.-J., Zeng, F., Liu, L., Mu, L.-M., Xie, H., Zhao, Y. L., Yan, Y., Wu, J.-S., & Hu, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s94467 · Cited by 50
Adapting conventional cancer treatment for immunotherapy
Qiao, J., Liu, Z., & Fu, Y. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1393-4 · Cited by 48
Adenovirus as vehicle for anticancer genetic immunotherapy
Gallo, P., Dharmapuri, S., Cipriani, B., & Monaci, P. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302619 · Cited by 45
Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells
Bakhshaiesh, T. O., Armat, M., Shanehbandi, D., Sharifi, S., Baradaran, B., Hejazi, M. S., & Samadi, N. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.13.5191 · Cited by 44
Self-citationNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?
Friberg, S. G., & Nyström, A. M. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0172-2 · Cited by 43
Rouleau, L., Antony, A. N., Bisetto, S., Newberg, A. B., Doria, C., Levine, M., Monti, D., & Hoek, J. B. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.031 · Cited by 43
Dual Targeting Biomimetic Liposomes for Paclitaxel/DNA Combination Cancer Treatment
Liu, G.-X., Fang, G.-Q., & Xu, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915287 · Cited by 42
Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery
Xu, M., Qian, J., Liu, X.-F., Liu, T., & Wang, H. (2015) · Materials Science and Engineering C · doi:10.1016/j.msec.2015.01.098 · Cited by 41
Theranostic Lipid Nanoparticles for Cancer Medicine
Charron, D. M., Chen, J., & Zheng, G. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-16555-4_5 · Cited by 40
Chan, K. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0183 · Cited by 39
Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines in vitro
Frajese, G. V., Benvenuto, M., Fantini, M. C., Ambrosin, E., Sacchetti, P., Masuelli, L., Giganti, M. G., Modesti, A., & Bei, R. (2016) · Oncology Letters · doi:10.3892/ol.2016.4506 · Cited by 39
Vitamin C-driven epirubicin loading into liposomes
Lipka, D., Gubernator, J., Filipczak, N., Barnert, S., Süss, Kozubek, & Legut, M. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47745 · Cited by 38
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer
Patankar, N. A., Waterhouse, D., Strutt, D., Anantha, M., & Bally, M. B. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9832-8 · Cited by 36
Cao, L., Zeng, Q., Xu, C., Shi, S., Zhang, Z., & Sun, X. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300602j · Cited by 36
Chemical Modifications Rescue Off-Target Effects of RNAi
Snøve, O., & Rossi, J. J. (2006) · ACS Chemical Biology · doi:10.1021/cb6002256 · Cited by 36
A Novel Aldehyde-Terminated Dendrimers: Synthesis and Cytotoxicity Assay
Hamidi, A., Sharifi, S., Davaran, S., Ghasemi, S., Omidi, Y., & Rashidi, M.-R. (2012) · Tabriz University of Medical Sciences · doi:10.5681/bi.2012.014 · Cited by 34
Self-citationSolving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats
Persons, D. A., & Baum, C. (2011) · Molecular Therapy · doi:10.1038/mt.2010.305 · Cited by 34
Utilizing AntagomiR (Antisense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells
Velu, C. S., & Grimes, H. L. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-008-3_15 · Cited by 33
Treatment of cancer patients in their last month of life: aimless chemotherapy
Assi, T., Rassy, E., Tabchi, S., Ibrahim, T., Moussa, T., Chebib, R., Karak, F. E., Farhat, F., Chahine, G. Y., Nasr, F. L., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2959-3 · Cited by 32
Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Chaudhury, A., & Das, S. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150118135107 · Cited by 31
Takahashi, Y., Yamaoka, K., Nishikawa, M., & Takakura, Y. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21398 · Cited by 30
Sriraman, S. K., Geraldo, V. P. N., Luther, E., Degterev, A., & Torchilin, V. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.037 · Cited by 28
Cited by
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
Biocompatibility of nanomaterials and their immunological properties
Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R., Mohammed, F. S., Halder, S., Xu, M., Wu, M. J., Bao, S., et al. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe5fa · Cited by 389
Lu, H., Zhang, S., Wang, J., & Chen, Q. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.783831 · Cited by 334
Metadata
- Authors
- Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S.
- Venue
- Materials Science and Engineering: C
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 71
- Pages
- 1327-1341
- ISSN
- 0928-4931 (ISSN-L)
- OpenAlex
- W2556797199
- Cited by
- 307
- References
- 212
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.